US Regulators Clear Agilent to Buy Stratagene | GenomeWeb
NEW YORK (GenomeWeb News) — The US Federal Trade Commission has cleared Agilent Technologies’ proposed acquisition of Stratagene, according to a notice on the FTC’s website.
 
Agilent in April offered to buy Stratagene for $246 million, or $10.94 per share.
 
At the time, Stratagene CEO Joseph Sorge said he plans to form a new company that will pay $6.6 million for some of Stratagene’s molecular diagnostics assets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.